CereVasc vil presentere data om sitt minimalt invasive CNS-leveringssystem på det kommende årsmøtet i American Society of Gen and Cell Therapy

BOSTON, Kan 4, 2023 / PRNewswire / - CereVasc, LLC, a privately held, clinical-stage, medical device company developing novel treatments for neurological diseases, announced today that data on its minimally invasive Central Nervous System (CNS) Delivery System will be presented for the first time at the American Society of Gene and Cell Therapy Annual Meeting being held on May 16-20, 2023i Los Angeles.

Details of the session:

Onsdag 17. mai, 12:XNUMX PST
Plakatøkt
Abstract Number 375

“We are excited to share the results of our in vivo investigation using the eShunt® platform to deliver gene therapy to the CNS,” said Dan Levangie, Chairman and CEO of CereVasc. “The gene and cell therapy community has made tremendous progress in bringing life-changing therapies to patients, but the route of administration for CNS focused therapies can be an obstacle to clinical success. We believe our novel approach has the potential to provide the community an attractive solution to common CNS delivery challenges,” continued Levangie. 

Om CereVasc, Inc.

Ligger i Massachusetts' helsesenter, CereVasc, Inc., er et venture-finansiert, medisinsk utstyrsselskap med fokus på utvikling av nye, minimalt invasive behandlinger for pasienter med nevrologiske sykdommer. Flaggskipsproduktet, eShunt-systemet, er ment å tilby den første minimalt invasive behandlingen for kommunikasjon av hydrocephalus (CH) og en forbedring av dagens standard for omsorg. eShunt-enhetskonseptet stammer fra Tufts Medical Center-leger Carl Heilman, MD, nevrokirurg og styreleder for nevrokirurgi, og Adel Malek, MD, PhD, nevrokirurg og sjef for nevrovaskulær kirurgi. Det patenterte eShunt-systemet inkluderer en endovaskulært implanterbar cerebral spinalvæske (CSF) shunt og leveringskomponenter, som er designet for å behandle CH uten invasiv kirurgi. For ytterligere informasjon, vennligst besøk vår nettside på www.cerevasc.com.

The eShunt® Device is an investigational device and not available for sale within or outside de forente stater.

Firmakontakt
DJ Cass
CereVasc, Inc.
djcass@cerevasc.com

Se originalt innhold for å laste ned multimedia:https://www.prnewswire.com/news-releases/cerevasc-to-present-data-on-its-minimally-invasive-cns-delivery-system-at-upcoming-american-society-of-gene-and-cell-therapy-annual-meeting-301812179.html

KILDE CereVasc, Inc.

• SEO-drevet innhold og PR-distribusjon. Bli forsterket i dag.
• PlatoAiStream. Web3 Data Intelligence. Kunnskap forsterket. Tilgang her.
• Minting the Future med Adryenn Ashley. Tilgang her.
• kilde: https://www.biospace.com/article/releases/cerevasc-to-present-data-on-its-minimally-invasive-cns-delivery-system-at-upcoming-american-society-of-gene-and-cell-therapy-annual-meeting/?s=93